• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.可能的通用价格竞争不足以控制口服抗癌疗法的价格。
JAMA Intern Med. 2017 Nov 1;177(11):1679-1680. doi: 10.1001/jamainternmed.2017.2788.
2
Endogenous versus exogenous generic reference pricing for pharmaceuticals.药品的内源性与外源性仿制药参考定价
Int J Health Econ Manag. 2017 Dec;17(4):413-432. doi: 10.1007/s10754-017-9216-x. Epub 2017 May 15.
3
Generic Price Competition For Specialty Drugs: Too Little, Too Late?专利药的仿制药价格竞争：为时过晚？
Health Aff (Millwood). 2018 May;37(5):738-742. doi: 10.1377/hlthaff.2017.1684.
4
The effect of generic competition on the price of brand-name drugs.仿制药竞争对品牌药价格的影响。
Health Policy. 2004 Apr;68(1):47-54. doi: 10.1016/j.healthpol.2003.07.007.
5
Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.中国抗肿瘤产品仿制药上市影响的中断时间序列分析
BMJ Open. 2018 Jul 16;8(7):e022328. doi: 10.1136/bmjopen-2018-022328.
6
The impact of generic substitution on price competition in Finland.仿制药替代对芬兰价格竞争的影响。
Eur J Health Econ. 2008 May;9(2):185-91. doi: 10.1007/s10198-007-0059-0. Epub 2007 May 17.
7
Price competition in pharmaceuticals - Evidence from 1303 Swedish markets.药品价格竞争 - 来自 1303 个瑞典市场的证据。
J Health Econ. 2018 Sep;61:1-12. doi: 10.1016/j.jhealeco.2018.06.009. Epub 2018 Jun 30.
8
OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.在美国销售的骨质疏松症药物：仿制药竞争、定价结构及支付方之间的差异
Int J Technol Assess Health Care. 2016 Jan;32(6):385-392. doi: 10.1017/S0266462316000623. Epub 2017 Jan 9.
9
What do pharmaceuticals really cost in the long run?从长远来看，药品的实际成本是多少？
Am J Manag Care. 2017 Aug;23(8):488-493.
10
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.生物类似药和仿制药不太可能改变美国癌症药物的成本曲线。
Lancet Oncol. 2017 Jan;18(1):22-23. doi: 10.1016/S1470-2045(16)30653-2.

引用本文的文献

1
Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea.是哪个因素降低了药品支出，是进入市场的企业数量还是价格差异？韩国更新后的仿制药市场。
Health Econ Rev. 2024 Aug 14;14(1):64. doi: 10.1186/s13561-024-00545-z.
2
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.保险机构和患者对转移性去势抵抗性前列腺癌治疗的药物支付情况。
JCO Oncol Pract. 2023 Apr;19(4):e600-e617. doi: 10.1200/OP.22.00645. Epub 2023 Jan 23.
3
Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study.韩国原研药的市场独占期：一项回顾性队列研究。
Front Public Health. 2021 Apr 6;9:654952. doi: 10.3389/fpubh.2021.654952. eCollection 2021.
4
Perceptions of Health-Care Workers of the Cost and Safety of Oral Oncolytic Agents for Patients: A Survey.医疗保健工作者对口腔溶瘤药物对患者的成本和安全性的看法：一项调查。
J Adv Pract Oncol. 2020 May-Jun;11(4):354-365. doi: 10.6004/jadpro.2020.11.4.3. Epub 2020 May 1.
5
Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.为什么个体层面的干预措施不够：口服抗癌药物依从性的系统层面决定因素。
Cancer. 2020 Aug 15;126(16):3606-3612. doi: 10.1002/cncr.32946. Epub 2020 May 21.

本文引用的文献

1
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.美国处方药价格居高不下：根源与改革前景。
JAMA. 2016;316(8):858-71. doi: 10.1001/jama.2016.11237.
2
Generic Drug Approvals Since the 1984 Hatch-Waxman Act.自1984年《哈奇-沃克斯曼法案》以来的仿制药批准情况。
JAMA Intern Med. 2016 Sep 1;176(9):1391-3. doi: 10.1001/jamainternmed.2016.3411.
3
Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure.口服抗癌药物上市后价格稳步上涨，表明缺乏竞争压力。
Health Aff (Millwood). 2016 May 1;35(5):805-12. doi: 10.1377/hlthaff.2015.1145.
4
Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014.2000 - 2014年商业健康保险计划报销的口服抗癌药物的药品定价趋势
JAMA Oncol. 2016 Jul 1;2(7):960-1. doi: 10.1001/jamaoncol.2016.0648.

可能的通用价格竞争不足以控制口服抗癌疗法的价格。

Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.

机构信息

Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill.

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

出版信息

JAMA Intern Med. 2017 Nov 1;177(11):1679-1680. doi: 10.1001/jamainternmed.2017.2788.

DOI:10.1001/jamainternmed.2017.2788
PMID:28892541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5820701/
Abstract

This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.

摘要

本研究通过抗癌药物卡培他滨失去专利保护来追踪其使用情况，以评估仿制药定价对口服抗癌药物成本的影响。